Prils Market Size

Prils Market size was valued at USD 2.13 Billion in 2023 and is expected to reach USD 4.7 Billion by the end of 2036, expanding at around 6.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of prils is assessed at USD 2.25 Billion. The growth of the market can be attributed to the increasing prevalence of high blood pressure. Lifestyle modifications and appropriate medication, such as prils, are frequently used to treat the disease.

When more people are diagnosed with hypertension and given prescriptions for blood pressure management, in turn, could increase the demand for market. According to estimates over 69 million senior adults in India are expected to have hypertension by the year 2050.

Factors that are believed to fuel the prils market growth include the rise in the pharmaceutical industry across the globe. As more people gain access to the medication, there may be an increase in demand as a result of greater accessibility and availability of prils in hospitals, pharmacies, and other locations.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of prils is assessed at USD 2.25 Billion.

The prils market size was valued at USD 2.13 Billion in 2023 and is expected to reach USD 4.7 Billion by the end of 2036, expanding at around 6.3% CAGR during the forecast period i.e., between 2024-2036. Rising geriatric population and the growing incidences of cardiovascular diseases are the major factors driving the market growth

Europe is estimated to hold the second-largest share of 31% by 2036, driven by increasing initiatives to assist the expansion of generic medications through pricing and reimbursement in the region.

Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited

Prils Market Size